The filing is supported by phase 3 REZILIENT3 data showing a median PFS of 14.5 vs 8.5 months with zipalertinib plus chemotherapy vs chemotherapy.
Commentary|Videos|April 30, 2025
Lung Cancer Experts Highlight the Significance and Limitations of ADCs
Lung cancer experts discuss successes and hesitations regarding the evolving use of antibody-drug conjugates in non–small cell lung cancer.
Advertisement
Advertisement
Hear from the following lung cancer experts about the evolving use of antibody-drug conjugates (ADCs) in non–small cell lung cancer (NSCLC):
Related to this article
Pooled phase 1/2 data support 10 mg/kg every 3 weeks as the provisional pivotal dose of the PD-1/VEGF bispecific antibody cesalatamig in previously treated NSCLC.
The top 5 OncLive TV videos of the week cover insights in NSCLC, gynecologic cancers, CRC, multiple myeloma, and NMIBC.
IL-1β blockade with canakinumab was well tolerated and reduced nodule size in patients with high-risk indeterminate pulmonary nodules.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Lung cancer experts outline some of the most crucial findings from ESMO 2026 that could affect future clinical decision-making.
Yale experts address borderline resectability, perioperative chemoimmunotherapy, pCR-guided adjuvant therapy, and osimertinib in early-stage NSCLC.
Misty D. Shields, MD, PhD, answers questions on ADCs, tarlatamab sequencing, first-line maintenance, subtyping, and transformed SCLC.
Advertisement
Advertisement